Table 3 Sensitivity analyses of FibroTest diagnostic values according to published studies

Characteristic (number of studies)

All (30)

0.80 0.78–0.82

0.84 0.83–0.86

Disease

   HCV (19)

0.79 0.76–0.82

0.85 0.82–0.87

   HBV (4)

0.77 0.74–0.81

0.80 0.77–0.84

   ALD (2)

0.88 0.81–0.84

0.86 0.80–0.92

   NAFLD (2)

0.81 0.70–0.91

0.84 0.76–0.92

   Mixed (3)

0.86 0.81–0.91

0.85 0.80–0.93

Design

   Prospective (19)

0.83 0.81–0.85*

0.86 0.84–0.88

   Retrospective (11)

0.76 0.73–0.78

0.82 0.80–0.84

Authors

   Independent (16)

0.80 0.77–0.83

0.85 0.82–0.88

   Mixed (5)

0.76 0.73–0.80

0.83 0.81–0.86

   Inventor (9)

0.83 0.79–0.87

0.84 0.81–0.88

Guidelines/Fresh

   No (7)

0.77 0.72–0.79

0.83 0.80–0.86

   Yes (23)

0.82 0.79–0.84**

0.84 0.83–0.86

Length biopsy

   < 18 (6)

0.81 0.76–0.86

0.84 0.80–0.87

   > = 18 (18)

0.81 0.78–0.84

0.85 0.83–0.87

Interval serum-biopsy

   > 30 days (8)

0.79 0.74–0.84

0.81 0.78–0.84

   < 30 (15)

0.80 0.78–0.83

0.85 0.83–0.87

Co-morbidity

   No (21)

0.79 0.77–0.81

0.85 0.83–0.87

   Yes (8)

0.83 0.78–0.88

0.83 0.80–0.87